The Case-Patient In March 2014, a 47-year-old woman was hospitalized at the Bernhard Nocht Clinic (Hamburg, Germany) with chills, nausea, and fever (temperature <40°C). The patient had a history of intravenous drug use (cocaine and benzodiazepines) and was currently enrolled in a methadone substitution program. She also had chronic hepatitis C virus infection that was successfully treated with pegylated interferon-α, ribavirin, and boceprevir. The patient had a sustained virologic response and negative results for hepatitis C virus RNA at follow-up without progression to liver fibrosis or cirrhosis.
At admission, her peripheral blood leukocyte count was 6.6 × 10 3 cells/μL, and her C-reactive protein level was increased (29 mg/L [reference value <5 mg/L]). Other routine serum and urine chemical test results were unremarkable. HIV-1/2 infection was not detected. Chest radiograph showed no abnormalities. Soft tissue abscess was not observed, but the patient admitted having injected cocaine and unknown crushed tablets intravenously the day before admission. Toxicologic screening showed highly increased levels of benzodiazepine (>5,000 ng/mL) and cocaine (>1,000 ng/mL) (reference values <20 ng/mL for both substances). Three blood cultures were collected before empiric antimicrobial therapy with intravenous ceftriaxone (2 g 1×/d) was given on day 1.
The next day, the patient's condition deteriorated. Her leukocyte count increased to 27.6 ×10 3 cells/μL, and C-reactive protein level increased to 112 mg/L. She was highly febrile and became hypotensive and tachycardic, which are compatible with severe sepsis. The patient responded rapidly to fluid substitution, became hemodynamically stable, and did not need vasopressors. Antimicrobial therapy was changed empirically to meropenem (1,000 mg 3×/d) on day 2.
After 18 h of culture incubation, microbial growth was detected in 3 aerobic blood culture bottles inoculated at admission. Gram staining showed gram-negative rods, and matrix-assisted laser desorption ionization/time-offlight mass spectrometry fingerprinting with direct sample deposition without extraction (Bruker Daltonim GmbH, Bremen, Germany) identified A. ursingii (score 2.19). A BLAST search (http://www.ncbi.nlm.nih.gov/BLAST) of partial 16S rRNA gene sequence was performed by using a taxonomy browser (http://www.ncbi.nlm.nih.gov) and showed 99% identity with the A. ursingii type strain NBRC110605 (GenBank accession no. LC014147.1).
Antimicrobial susceptibility testing was performed by using Vitek 2 (bioMérieux, Nürtingen, Germany). Results showed susceptibility to imipenem (MIC <0.25 mg/mL), meropenem (<0.25 mg/mL), gentamicin (<1 mg/mL), and ciprofloxacin (<0.25 mg/mL) and resistance to ceftriaxone (32 mg/mL).
The patient became afebrile the next day, her clinical symptoms improved, and laboratory parameters of (13) reported 113 case-patients with Acinetobacter spp. bloodstream infections in Norway; 3 (2.6%) were with A. ursingii, but clinical details of these patients were not provided. This relatively high incidence is consistent with results from the Netherlands (10) and Northern Ireland (11).
In most reports, A. ursingii isolates were more susceptible to antimicrobial drugs than A. baumannii isolates (4, 6, 8, 12, 13) . However, Endo et al. (9) reported an IMP-1-producing, carbapenem-resistant A. ursingii isolate from a patient in Japan with a nosocomial bloodstream infection.
A. ursingii isolates are usually resistant to cephalosporins (3, 5, 8) , as was the isolate from the patient we report, which explains the progression from severe sepsis when she was empirically given ceftriaxone to rapid clinical improvement after administration of meropenem. Máder et al. (6) reported a premature infant with an A. ursingii bloodstream infection also given a cephalosporin (ceftazidime). However, the infant received a combination with amikacin and immunoglobulins for 3 weeks. The infant survived and was discharged.
These findings suggest that A. ursingii is an emerging and serious clinical pathogen that is often involved in nosocomial bloodstream infections and associated with use of intravascular catheters. Its natural habitat remains unclear, but so far, it has only been isolated from human clinical sources. The frequency and clinical role of A. ursingii might have been underestimated because species identification by phenotypic and semiautomated identification methods is unreliable. For example, Vitek 2 has misidentified A. ursingii as Bordetella bronchiseptica (6, 8) . The most recent software version for Vitek 2 enabled unambiguous identification of A. ursingii (H. Seifert, pers. comm.).
We report a case of community-acquired bloodstream infection and severe sepsis caused by A. ursingii that was probably associated with intravenous drug use in an immunocompetent patient. This report also highlights the usefulness of matrix-assisted laser desorption/ionization time-offlight mass spectrometry for identification of Acinetobacter spp. We believe that this technology might improve correct species identification of Acinetobacter spp., including A. ursingii, in routine clinical practice and help elucidate the prevalence and clinical role of this emerging pathogen.
